PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
15121897-4	2004	The 11mer daunomycin-conjugated GT (dauno-GT11) TFO targeted a sequence upstream of the P2 promoter, a site known to be critical for transcription of the c-myc gene.	tfo	48-51	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	154-159	
15121897-7	2004	The daunomycin-conjugated TFO inhibited transcription in vitro and reduced c-myc promoter activity in prostate and breast cancer cells.	tfo	26-29	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	75-80	
24824865-4	2014	We then investigated the possibility of using ultrasmall 2 nm nanoparticles as carriers for nuclear delivery of a triplex-forming oligonucleotide (TFO) that binds to the c-myc promoter.	tfo	147-150	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	170-175	
10919652-2	2000	The purpose of the present work was to characterize the antigene and antiproliferative activity of a triple helix-forming oligonucleotide (TFO) targeted to a homopurine-homopyrimidine sequence in the P2 promoter of the c-myc gene.	tfo	139-142	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	219-224	
10529208-8	1999	Electrophoretic mobility shift assay revealed enhanced binding of TFO to a target duplex containing promoter region sequence of c-myc oncogene.	tfo	66-69	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	128-133	
10529208-9	1999	Treatment of MCF-7 cells with the TFO complexed with 0.5 microM 3-4-3-4-3 suppressed c-myc mRNA level by 65%, as determined by Northern blot analysis.	tfo	34-37	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	85-90	
7794930-8	1995	We have also shown that the P2-targeted TFO is a potent and specific inhibitor of c-myc transcription in vitro.	tfo	40-43	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	82-87	
7794930-9	1995	These data demonstrate that this novel TFO inhibits transcription of the c-myc P2 promoter.	tfo	39-42	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	73-78	
23681918-3	2014	Triplex-forming oligonucleotides (TFOs) were used to target site-specific DNA damage to the human c-MYC oncogene, thereby inducing replication-independent, unscheduled DNA repair synthesis (UDS) preferentially in the TFO-targeted region.	tfo	34-37	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	98-103	
23681918-7	2014	Specific TFO binding to the genomic c-MYC gene was demonstrated, and TFO-induced DNA damage was confirmed by NBS1 accumulation, supporting a mechanism of enhanced efficacy of GEM via TFO-targeted DNA damage-induced UDS.	tfo	9-12	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	36-41	
24824865-5	2014	Compared to free TFO, the nanoparticle-conjugated TFO was more effective at reducing c-myc RNA and c-myc protein, which resulted in reduced cell viability.	tfo	17-20	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	85-90	
24824865-5	2014	Compared to free TFO, the nanoparticle-conjugated TFO was more effective at reducing c-myc RNA and c-myc protein, which resulted in reduced cell viability.	tfo	17-20	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	99-104	
24824865-5	2014	Compared to free TFO, the nanoparticle-conjugated TFO was more effective at reducing c-myc RNA and c-myc protein, which resulted in reduced cell viability.	tfo	50-53	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	85-90	
24824865-5	2014	Compared to free TFO, the nanoparticle-conjugated TFO was more effective at reducing c-myc RNA and c-myc protein, which resulted in reduced cell viability.	tfo	50-53	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	99-104